Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SkinBioTherapeutics ( (GB:SBTX) ) just unveiled an update.
SkinBioTherapeutics has issued 259,472 new ordinary shares following the exercise of share options granted to a former employee at the time of its IPO, with admission of the new stock to trading on AIM scheduled for 13 February 2026. The enlarged share capital will comprise 259,168,671 ordinary shares, a new total that will be used by investors to calculate disclosure thresholds for changes in significant holdings under UK transparency rules.
The share issuance marginally dilutes existing shareholders but reflects the crystallisation of long-standing incentive arrangements dating back to the company’s market listing. By clarifying the updated voting rights and share count, the company provides greater visibility for market participants monitoring ownership positions and regulatory reporting obligations.
The most recent analyst rating on (GB:SBTX) stock is a Hold with a £19.50 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
Spark’s Take on GB:SBTX Stock
According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and negative operating/free cash flow) despite strong revenue growth and a relatively conservative balance sheet. Technicals are supportive due to positive momentum, but overbought signals temper that strength. Valuation remains challenging because losses make the P/E less meaningful and no dividend yield is available.
To see Spark’s full report on GB:SBTX stock, click here.
More about SkinBioTherapeutics
SkinBioTherapeutics plc is a UK-based life science company focused on skin health, built around its proprietary SkinBiotix platform developed with the University of Manchester. Its core business targets the skin healthcare market across five pillars, led by cosmetic skincare via a partnership with Croda and gut-skin axis food supplements sold under the AxisBiotix brand through direct channels, Amazon and selected Superdrug stores.
Average Trading Volume: 1,308,242
Technical Sentiment Signal: Buy
Current Market Cap: £52.43M
Learn more about SBTX stock on TipRanks’ Stock Analysis page.